Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

fruit

- PMLiVE

Merck claims first-ever okay for Ebola vaccine, in Europe

Comes shortly after J&J filed its Ebola candidate with EMA

- PMLiVE

UK biotech Evgen craters on failed stroke trial

Shares in the biotech more than halved following the news

- PMLiVE

Otsuka presses on with Alzheimer’s agitation drug

Surprise announcement comes on the heels of phase 3 trial fail

- PMLiVE

Pharmaceutical innovation in the APAC region

A first-of-its-kind study paints a vivid picture of the APAC region’s future

Patient journey mapping: exploring the clinical and the emotional journey

By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...

OPEN Health

- PMLiVE

Harnessing the power of cultural insight to build meaningful healthcare strategies

By Gemma McCarthy

- PMLiVE

Sandoz expands into Japan with €400m Aspen deal

Will gain presence in third largest generics market in the world

Roche Basel Switzerland

Roche’s Spinraza, Zolgensma rival risdiplam hits the mark in SMA

Will file for approval in US and other world markets before end of the year

- PMLiVE

Precision medicine at Blue Latitude Health

At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...

Blue Latitude Health

- PMLiVE

NICE backs first cannabis-based drugs, both from GW Pharma

Approved to treat patients with epilepsy and multiple sclerosis

Novartis day

Novartis makes case for NASH candidate tropifexor

Race to market intensifies as rivals strive to win first-in-class

- PMLiVE

We’ll need more than a spoonful of sugar to counter vaccine hesitancy

By Satinder Phull

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links